HomeCompareZUMRF vs ABBV

ZUMRF vs ABBV: Dividend Comparison 2026

ZUMRF yields 4000.00% · ABBV yields 3.06%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 ZUMRF wins by $7175340620755.77M in total portfolio value
10 years
ZUMRF
ZUMRF
● Live price
4000.00%
Share price
$0.05
Annual div
$2.00
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$7175340620755.87M
Annual income
$6,839,006,593,197,835,000.00
Full ZUMRF calculator →
ABBV
AbbVie Inc.
● Live price
3.06%
Share price
$217.44
Annual div
$6.65
5Y div CAGR
40.6%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$102.3K
Annual income
$24,771.77
Full ABBV calculator →

Portfolio growth — ZUMRF vs ABBV

📍 ZUMRF pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodZUMRFABBV
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, ZUMRF + ABBV cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
ZUMRF pays
ABBV pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

ZUMRF
Annual income on $10K today (after 15% tax)
$340,000.00/yr
After 10yr DRIP, annual income (after tax)
$5,813,155,604,218,160,000.00/yr
ABBV
Annual income on $10K today (after 15% tax)
$259.96/yr
After 10yr DRIP, annual income (after tax)
$21,056.00/yr
At 15% tax rate, ZUMRF beats the other by $5,813,155,604,218,139,000.00/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of ZUMRF + ABBV for your $10,000?

ZUMRF: 50%ABBV: 50%
100% ABBV50/50100% ZUMRF
Portfolio after 10yr
$3587670310377.99M
Annual income
$3,419,503,296,598,930,000.00/yr
Blended yield
95.31%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on ABBV right now

ZUMRF
No analyst data
Altman Z
0.8
Piotroski
3/9
ABBV
Analyst Ratings
27
Buy
12
Hold
1
Sell
Consensus: Buy
Price Target
$256.15
+17.8% upside vs current
Range: $223.00 — $299.00
Altman Z
2.0
Piotroski
8/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

ZUMRF buys
0
ABBV buys
0
No recent congressional trades found for ZUMRF or ABBV in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricZUMRFABBV
Forward yield4000.00%3.06%
Annual dividend / share$2.00$6.65
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR0%40.6%
Portfolio after 10y$7175340620755.87M$102.3K
Annual income after 10y$6,839,006,593,197,835,000.00$24,771.77
Total dividends collected$7152397773804.84M$61.0K
Payment frequencyquarterlyquarterly
SectorStockHealthcare

Year-by-year: ZUMRF vs ABBV ($10,000, DRIP)

YearZUMRF PortfolioZUMRF Income/yrABBV PortfolioABBV Income/yrGap
1← crossover$410,700$400,000.00$11,550$430.00+$399.1KZUMRF
2$15,792,720$15,353,271.03$13,472$627.96+$15.78MZUMRF
3$568,657,142$551,758,931.89$15,906$926.08+$568.64MZUMRF
4$19,176,207,860$18,567,744,718.20$19,071$1,382.55+$19176.19MZUMRF
5$605,696,028,890$585,177,486,479.73$23,302$2,095.81+$605696.01MZUMRF
6$17,922,210,653,594$17,274,115,902,681.27$29,150$3,237.93+$17922210.62MZUMRF
7$496,869,793,504,300$477,693,028,104,954.00$37,536$5,121.41+$496869793.47MZUMRF
8$12,908,672,105,251,704$12,377,021,426,202,104.00$50,079$8,338.38+$12908672105.20MZUMRF
9$314,330,866,876,668,540$300,518,587,724,049,200.00$69,753$14,065.80+$314330866876.60MZUMRF
10$7,175,340,620,755,871,000$6,839,006,593,197,835,000.00$102,337$24,771.77+$7175340620755.77MZUMRF

ZUMRF vs ABBV: Complete Analysis 2026

ZUMRFStock

ZoomerMedia Limited operates as a multimedia company in Canada. The company operates through five segments: Television, Radio, Print, Royalty, and Other Operations. It is involved in the business of television, radio, magazine, Internet, conferences, and trade shows primarily for the 45 plus age group. The company's television properties include Vision TV, a multi-cultural and multi-faith specialty television service; ONE TV, which offers fitness, healthy living, and entertainment programs; JoyTV and Faith TV, channels for broadcasting Christian and local programming; and TVL Channel 5, a linear television channel guide available to households. It also operates various radio stations, such as CFMZ-FM Toronto and CFMX-FM Cobourg; CFMO-FM Collingwood; CFZM-AM 740 Toronto and CFZM-FM 96.7FM Toronto – Zoomer Radio; and Toronto's Timeless Hits station. In addition, the company publishes Zoomer magazine; and On The Bay Magazine, a regional lifestyle magazine published quarterly for the 20 towns and villages of Southern Georgian By, Ontario, as well as Tonic magazine, a regional health and wellness magazine published for every two months and distributed in Toronto. Further, it provides online content services targeting the 45plus age group primarily through EverythingZoomer.com and blogTO.com, as well as CARP.ca, VisionTV.ca, ZoomerRadio.ca, and ClassicalFM.ca. Additionally, the company produces ZoomerShows, an annual consumer shows directed to the Zoomer demographic; and ideaCity, an annual Canadian conference. ZoomerMedia Limited was founded in 2008 and is based in Toronto, Canada.

Full ZUMRF Calculator →

ABBVHealthcare

AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheumatoid arthritis in adult patients; IMBRUVICA to treat adult patients with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), and VENCLEXTA, a BCL-2 inhibitor used to treat adults with CLL or SLL; and MAVYRET to treat patients with chronic HCV genotype 1-6 infection. It also provides CREON, a pancreatic enzyme therapy for exocrine pancreatic insufficiency; Synthroid used in the treatment of hypothyroidism; Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation; Lupron for the palliative treatment of advanced prostate cancer, endometriosis and central precocious puberty, and patients with anemia caused by uterine fibroids; and Botox therapeutic. In addition, the company offers ORILISSA, a nonpeptide small molecule gonadotropin-releasing hormone antagonist for women with moderate to severe endometriosis pain; Duopa and Duodopa, a levodopa-carbidopa intestinal gel to treat Parkinson's disease; Lumigan/Ganfort, a bimatoprost ophthalmic solution for the reduction of elevated intraocular pressure (IOP) in patients with open angle glaucoma (OAG) or ocular hypertension; Ubrelvy to treat migraine with or without aura in adults; Alphagan/ Combigan, an alpha-adrenergic receptor agonist for the reduction of IOP in patients with OAG; and Restasis, a calcineurin inhibitor immunosuppressant to increase tear production, as well as other eye care products. AbbVie Inc. has a research collaboration with Dragonfly Therapeutics, Inc. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.

Full ABBV Calculator →
📬

Get this ZUMRF vs ABBV comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

ZUMRF vs SCHDZUMRF vs JEPIZUMRF vs OZUMRF vs KOZUMRF vs MAINZUMRF vs JNJZUMRF vs MRKZUMRF vs PFE

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.